Article Figures & Data
Figures
- Figure 1.
Study design. The date of the first leukotriene receptor antagonist (LTRA) prescription was defined as the index date and, for LTRA nonusers, the index date was defined as the date of bronchial asthma diagnosis plus the period between the date of bronchial asthma diagnosis and the date of first prescription of LTRA for the corresponding LTRA users. The period required for the onset of LTRA effects was specified as 1 year. Start of follow-up was defined as 1 year after the index date. The conditions marking the end of the follow-up period included: 1) cancer onset, 2) censoring for loss of follow-up, and 3) the end of observation period in the database (December 31, 2015), defined as the earliest day of these events.
- Figure 2.
The formula of administration days of basal dose of leukotriene receptor antagonist (LTRA).
- Figure 3.
Study flowchart. Patients with bronchial asthma over 40 years old at diagnosis were extracted from large population-based medical information databases. Excluded patients had exclusion criteria 1-4. Patients were then divided into leukotriene receptor antagonist (LTRA) users and LTRA non-users. Patients with exclusion criteria 1-5 were removed from LTRA users. The propensity score (PS) was calculated by logistic regression using covariates significant in two groups. LTRA users and non-users were matched 1:1 using PS values. If LTRA non-users had exclusion criteria 1-3, they were removed and their corresponding LTRA users were matched to other LTRA non-users again. This was done until there were no matching partners for LTRA users.
Tables
In this issue
Jump to section
Related Articles
Cited By...
- No citing articles found.